Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed

Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed

The aim of this study was to investigate the effects of various parameters at each control strategy in drug product degradation on the stability of pemetrexed in injectable aqueous solution. A forced degradation study confirmed that oxidation is the main mechanism responsible for the degradation of...

Full description

Bibliographic Details
Main Authors:	Dong Han Won, Heejun Park, Eun-Sol Ha, Yong Min Kim, Hyung Don Hwang, Sun Woo Jang, Min-Soo Kim
Format:	Article
Language:	English
Published:	MDPI AG 2020-01-01
Series:	Pharmaceutics
Subjects:	pemetrexed stability aqueous injectable solution oxidation control strategy
Online Access:	https://www.mdpi.com/1999-4923/12/1/46

Similar Items

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
by: Goyal Pankaj, et al.
Published: (2016-01-01)

Pemetrexed induced pneumonitis
by: Binod Dhakal, et al.
Published: (2011-11-01)

New Polymorphic Forms of Pemetrexed Diacid and Their Use for the Preparation of Pharmaceutically Pure Amorphous and Hemipentahydrate Forms of Pemetrexed Disodium
by: Olga Michalak, et al.
Published: (2015-07-01)

Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung
by: Kim D. H., et al.
Published: (2015-06-01)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)

Synthesis and Physicochemical Characterization of the Impurities of Pemetrexed Disodium, an Anticancer Drug
by: Olga Michalak, et al.
Published: (2015-05-01)

Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
by: Sun Young JUNG, et al.
Published: (2011-01-01)

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy  in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients  with Advanced Non-small Cell Lung Cancer
by: Junling LI, et al.
Published: (2012-03-01)

Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease
by: Jieun Yang, et al.
Published: (2022-04-01)

A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice
by: Samson A. Iwhiwhu, et al.
Published: (2024-10-01)

Activity of pemetrexed in recurrent, metastatic sacral chordoma: A case report
by: Dominique G. Celestino, et al.
Published: (2025-03-01)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
by: Ying He, et al.
Published: (2022-05-01)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
by: Yan Wang, et al.
Published: (2018-03-01)

Clinical Investigation of Efficacy of Third-line and Beyond Pemetrexed Treatment in Advanced Non-squamous Non-small Cell Lung Cancer
by: Fei YU, et al.
Published: (2012-02-01)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
by: Schuette W, et al.
Published: (2017-11-01)

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
by: Xiaoyan Si, et al.
Published: (2020-08-01)

Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib
by: Biao WU, et al.
Published: (2010-08-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review
by: Tito Zattera, et al.
Published: (2017-04-01)

Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells
by: Buqué Aitziber, et al.
Published: (2012-04-01)

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
by: Joon‐Young Yoon, et al.
Published: (2019-04-01)

A Comparative Study Between Pemetrexed and Taxanes as First Line Treatment of Metastatic Lung Adenocarcinoma
by: Sarmad Qahtan Al-Salihi,, et al.
Published: (2024-06-01)

A Case of Posterior Reversible Encephalopathy Syndrome Induced by Cisplatin/Pemetrexed Chemotherapy for Lung Cancer
by: Masashi Ishihara, et al.
Published: (2017-03-01)

Preparation, Characterization, and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin
by: Rudra Pangeni, et al.
Published: (2018-09-01)

Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting
by: Heidi Egloff, et al.
Published: (2014-07-01)

A meta-analysis of Pemetrexed plus Platinum Chemotherapy versus Gemcitabine plus Platinum Chemotherapy for Advanced Non-small Cell Lung Cancer
by: Jin JIANG, et al.
Published: (2011-01-01)

Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS
by: Andy Liu, et al.
Published: (2023-09-01)

Are 5-7 Days of Folic Acid Supplementation Necessary prior to Pemetrexed Observations from a Case Series
by: Benjamin R. Griffin, et al.
Published: (2013-06-01)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
by: Ruby Maharjan, et al.
Published: (2019-07-01)

Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non‐small cell lung cancer
by: Runbin Sun, et al.
Published: (2023-09-01)

Edema of the face and extremities secondary to pemetrexed
by: Thomas Doyle, MS, et al.
Published: (2023-08-01)

Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer
by: Chung-Yu Chen, et al.
Published: (2020-10-01)

Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems
by: Ciekot Jarosław, et al.
Published: (2016-03-01)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
by: Shao-Lun Lu, et al.
Published: (2016-08-01)

Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
by: A. M. Lozhkina, et al.
Published: (2018-11-01)

Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study
by: Yang Wu, et al.
Published: (2024-12-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study
by: Wei Fang, et al.
Published: (2024-08-01)